Actual and Potential Agents and Biomarkers in the Treatment of Cancer

ISSN: 1875-5992 (Online)
ISSN: 1871-5206 (Print)

Volume 17, 14 Issues, 2017

Download PDF Flyer

Anti-Cancer Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Cancer Agents

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 27th of 59 in Chemistry, Medicinal

Submit Abstracts Online Submit Manuscripts Online

Michelle Prudhomme
Institut de Chimie de Clermont-Ferrand
Université Clermont Auvergne

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.722
5 - Year: 2.849

Actual and Potential Agents and Biomarkers in the Treatment of Cancer

Anti-Cancer Agents in Medicinal Chemistry, 9(5): 500-516.

Author(s): M. P. Carrera, M. J. Ramirez-Exposito and J M Martinez-Martos.

Affiliation: Department of Health Sciences, Physiology. Faculty of Experimental and Health Sciences University of Jaen, Campus Universitario “Las Lagunillas” E- 23071, Jaen, Spain.


It is well known that cancer is defined as a group of diseases that differ both regarding the tissues they affect as well as their origin. For this reason, much effort is being made in the development of new drugs with the aim of increasing survival and patients quality of life. There is already a wide spectrum of anti-cancer agents that follow different mechanisms of action, such as the inhibitors of topoisomerases I and II and anti-mitotic chemicals, among others. Usually, these drugs are able to increase the patients survival, although their toxicity worsens the patients quality of life. Therefore, we should seriously consider alternative mechanisms, as well as the co-administration of these drugs with non-toxic compounds, such as melatonin or retinoic acid. This would increase the toxic effects of these drugs at low doses. Obviously, a better understanding of modified physiological systems during the development of these diseases would improve the diagnostic tools. This would be translated, in turn, into a higher survival index. The alteration of the proteolytic enzymes involved in the renin-angiotensin system and in the regulation of the gonadotrophins and TRH synthesis in breast cancer are examples of the above. These two proteins are regulated by the same enzyme, pyrrolidon carboxipeptidase, and both are directly involved in the initiation and development of breast cancer. Therefore, the aim of the present review is to revise the different options available at present to improve patients survival and to show alternative mechanisms that may be beneficial to patients well being.


Chemotherapy, cancer, oxidative stress, natural compounds, renin-angiotensin system.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 9
Issue Number: 5
First Page: 500
Last Page: 516
Page Count: 17
DOI: 10.2174/187152009788451824
Price: $58

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science